Solid Biosciences LLC (SLDB) - Net Assets
Based on the latest financial reports, Solid Biosciences LLC (SLDB) has net assets worth $217.95 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($273.91 Million) and total liabilities ($55.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Solid Biosciences LLC (SLDB) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $217.95 Million |
| % of Total Assets | 79.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | 3.91% |
| 10-Year Change | N/A |
| Growth Volatility | 40.85 |
Solid Biosciences LLC - Net Assets Trend (2015–2024)
This chart illustrates how Solid Biosciences LLC's net assets have evolved over time, based on quarterly financial data. Also explore Solid Biosciences LLC asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Solid Biosciences LLC (2015–2024)
The table below shows the annual net assets of Solid Biosciences LLC from 2015 to 2024. For live valuation and market cap data, see Solid Biosciences LLC (SLDB) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $137.25 Million | +8.51% |
| 2023-12-31 | $126.48 Million | -40.25% |
| 2022-12-31 | $211.67 Million | +1.66% |
| 2021-12-31 | $208.21 Million | +57.63% |
| 2020-12-31 | $132.09 Million | +65.01% |
| 2019-12-31 | $80.05 Million | -36.06% |
| 2018-12-31 | $125.18 Million | +311.25% |
| 2017-12-31 | $-59.26 Million | -56.41% |
| 2016-12-31 | $-37.89 Million | -90.14% |
| 2015-12-31 | $-19.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Solid Biosciences LLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 71573900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $40.00K | 0.03% |
| Other Comprehensive Income | $47.00K | 0.03% |
| Other Components | $920.61 Million | 670.77% |
| Total Equity | $137.25 Million | 100.00% |
Solid Biosciences LLC Competitors by Market Cap
The table below lists competitors of Solid Biosciences LLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kido Group Corp
VN:KDC
|
$482.28 Million |
|
Prothena Corporation plc
NASDAQ:PRTA
|
$482.32 Million |
|
More Provident Funds
TA:MPP
|
$482.42 Million |
|
Jiangsu Yida Chemical Co Ltd Class A
SHE:300721
|
$482.45 Million |
|
Liuzhou Liangmianzhen Co Ltd
SHG:600249
|
$482.09 Million |
|
Ambassador Hotel Ltd
TW:2704
|
$482.06 Million |
|
Sungwoo Hitech Co. Ltd
KQ:015750
|
$481.92 Million |
|
Shenzhen Crastal Technology Co Ltd
SHE:300824
|
$481.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Solid Biosciences LLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 126,481,000 to 137,246,000, a change of 10,765,000 (8.5%).
- Net loss of 124,697,000 reduced equity.
- Share repurchases of 5,111,000 reduced equity.
- New share issuances of 127,227,000 increased equity.
- Other comprehensive income increased equity by 32,000.
- Other factors increased equity by 13,314,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-124.70 Million | -90.86% |
| Share Repurchases | $5.11 Million | -3.72% |
| Share Issuances | $127.23 Million | +92.7% |
| Other Comprehensive Income | $32.00K | +0.02% |
| Other Changes | $13.31 Million | +9.7% |
| Total Change | $- | 8.51% |
Book Value vs Market Value Analysis
This analysis compares Solid Biosciences LLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.12x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-52.66 | $7.13 | x |
| 2016-12-31 | $-65.80 | $7.13 | x |
| 2017-12-31 | $-27.57 | $7.13 | x |
| 2018-12-31 | $56.44 | $7.13 | x |
| 2019-12-31 | $29.80 | $7.13 | x |
| 2020-12-31 | $38.15 | $7.13 | x |
| 2021-12-31 | $29.25 | $7.13 | x |
| 2022-12-31 | $24.87 | $7.13 | x |
| 2023-12-31 | $6.36 | $7.13 | x |
| 2024-12-31 | $3.36 | $7.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Solid Biosciences LLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -90.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.37x
- Recent ROE (-90.86%) is below the historical average (-51.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $374.30K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.10 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-46.19 Million |
| 2018 | -59.75% | 0.00% | 0.00x | 1.12x | $-87.32 Million |
| 2019 | -146.44% | 0.00% | 0.00x | 1.29x | $-125.23 Million |
| 2020 | -66.84% | -2647.38% | 0.02x | 1.30x | $-101.50 Million |
| 2021 | -34.67% | -530.01% | 0.06x | 1.12x | $-93.01 Million |
| 2022 | -40.62% | -1062.28% | 0.03x | 1.23x | $-107.15 Million |
| 2023 | -75.91% | 0.00% | 0.00x | 1.30x | $-108.66 Million |
| 2024 | -90.86% | 0.00% | 0.00x | 1.37x | $-138.42 Million |
Industry Comparison
This section compares Solid Biosciences LLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,740,057
- Average return on equity (ROE) among peers: -43.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Solid Biosciences LLC (SLDB) | $217.95 Million | 0.00% | 0.26x | $482.26 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.74 Billion |
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular ta… Read more